First Bight Ventures: Veronica Breckenridge shares how to get funded in 2026 Investment Climate Podcast: Fundraising Playbooks From Food Tech CEOs and VCs In this podcast series, Alex Shandrovsky interviews investors about benchmarks for funding Alt Proteins in 2025 and uncovers the investment playbooks of successful Climate Tech CEOs and Leading VCs. Podcast Host Alex Shandrovksy is a strategic advisor to numerous global food tech accelerators and companies, including alternative proteins and cellular agriculture leaders. His focus is on investor relations and post-raise scale for agrifood tech companies. This podcast is syndicated through our media partners, Foodtech Weekly and Vegconomist. Episode 63: First Bight Ventures: Veronica Breckenridge shares how to get funded in 2026 In this episode, I sit down with Veronica Breckenridge, Managing Partner of First Bight Ventures, for a deep, no-nonsense look at why most industrial biotech companies fail—and how a different investment model can actually work. We talk about why “industrial biotech is not venture-backable” is a lazy myth, how CapEx-heavy businesses can deliver strong equity returns if founders know how to finance assets without burning dilution, and why SaaS-style thinking has done real damage to biomanufacturing. Veronica unpacks her thesis around drop-in, cost-parity technologies, design-for-manufacturability, early strategic validation, and why she avoids product-market risk like the plague. We dig into her portfolio decisions, including a rare AgriFood bet, the role of non-dilutive capital (including DoD and government funding), why green premiums don’t exist but health premiums do, and why most exits in this space will be disciplined M&A—not unicorn fantasies. If you’re a founder or investor navigating deep tech, bio-based chemicals, or industrial biotech in the post-hype era, this conversation is a masterclass in realism, capital efficiency, and how to build companies that can actually survive—and exit. Key Facts First Bight Ventures: Goal: Capture the massive value creation opportunity, a multi-trillion-dollar industrial transition from petroleum to biology-based manufacturing for chemicals and materials.Alex’s Top Findings: Industrial Biotech Is Venture-Backable (If You Finance CapEx Correctly). Veronica’s core contrarian belief is that industrial biotech isn’t “uninvestable” — founders just finance it incorrectly. When CapEx is funded with project finance, credit, or non-dilutive capital instead of equity, companies can still generate strong venture-style returns without relying on SaaS-like margins. ” The biggest contrarian I think for me is industrial biotech is not worth investing. My belief is that's not true. 'cause if you know how to leverage, if you understand how to finance that CapEx, without using equity capital, you could still grow an equity. Efficient model in term of going to market and commercialize so that your equity return can be still solid.”Early Strategic Buyers De-Risk Exit, Not Just Commercialization. First Bight introduces strategics early — not for optics, but to define specs, manufacturability, and eventual M&A pathways. Veronica won’t invest unless she already sees credible strategic interest shaping the company’s trajectory. “I don’t invest unless I already feel like I’m working with the strategic — they help define the specs you must hit to be acquired.”Capital Efficiency Is a Strategy, Not A Constraint. Veronica repeatedly contrasts founders who “burn equity” versus those who design the company to qualify for debt, project finance, and grants. Her point is blunt: unless you’re Elon Musk, you can’t raise unlimited capital to pay for expensive mistakes — so the business must be structured to avoid them. “You’re not Elon Musk… you’re
